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Clinical Presentation and Therapy of Primary Immune 
Thrombocytopenia Resistant to Splenectomy 
Aleksandar Kara-Jovanović,1 Nada Suvajdžić-Vuković. 2 
Abstract 
Background: A satisfactory therapeutic response is achieved with splenectomy in 60–80% of the patients diagnosed with immune thrombocytopenic purpura 
(ITP). There is an ongoing consensus on the short-term efficacy of splenectomy, however, its long-term efficacy remains controversial. Our aim was to 
establish the frequency of resistance and relapse after splenectomy, the occurrence of complications, the therapeutic strategies and the drug efficacy in 
splenectomy-resistant ITP. Methods: We retrospectively analyzed 138 adult ITP patients who had been previously diagnosed and treated at the Clinic of 
Hematology, Clinical Center of Serbia, and who underwent splenectomy between 1987 and 2018. Results: Of the 138 ITP patients, 20.3% (n=28/138) were 
refractory to splenectomy, 11.6% (n=16/138) relapsed and 8.7% (n=12/138) were primarily resistant. The average post-splenectomy follow-up period was 
117 months (range 3-474). The average follow-up period of the patients resistant to splenectomy was 147 months (range 23-474). Of the patients refractory 
to splenectomy, 67.8% (n=19/28) showed a good therapeutic response: 49% (n=14/28) complete remission and 18.8% (n=5/28) partial remission. The 
response was usually achieved using the following drugs: romiplostim (100%), eltrombopag (75%), cyclosporine (66.67%), mycophenolate mofetil (50%), 
danazol (50%) and corticosteroids (40.9%). Hemorrhagic and non-hemorrhagic complications occurred in 78.6% (n=22/28) and 28.6% (n=8/28) of the 
patients, respectively. Conclusion: Splenectomy remains a very efficient therapeutic modality for the treatment of ITP patients with a high percentage of 
splenectomy-resistant patients achieving remission. Thrombopoietin receptor agonists have shown exceptional results so far in the treatment of refractory 
ITP patients. 
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Introduction 
Immune thrombocytopenic purpura (ITP) is an immune-mediated 
acquired disease of adults and children characterized by a transient or 
persistent decrease of the platelet count below 100×109/L in the 
absence of evident predisposing factors, and by an increased risk of 
bleeding.1-2 The incidence of primary ITP in adults is 3.3/100 000 adults 
per year with a prevalence of 9.5 per 100 000 adults.1 In 2009, the 
International Working Group (IWG) presented standards for definitions, 
classification criteria, and outcome measures. The classification scheme 
included division by disease phase: newly diagnosed ITP (<3 months), 
persistent ITP (3–12 months), and chronic ITP (>12 months). Refractory 
ITP is defined as a disease that does not respond to or relapses after 
splenectomy and that requires treatment to reduce the risk of clinically 
significant bleeding.1 
 
The clinical presentation of ITP is most often asymptomatic or with a 
varying bleeding tendency. The severity of bleeding frequently 
correlates with a low platelet count and older age. However, many 
patients with ITP do not experience significant bleedings despite having 
severe thrombocytopenia.3-4 Mucocutaneous bleeding (epistaxis, 
menorrhagia, gingival and gastrointestinal bleeding) is the most 
common clinical manifestation of ITP. Intracranial hemorrhage is the 
most worrisome complication of ITP, with an incidence of 6/340 adults 
newly diagnosed with ITP.5 Patients with ITP have an increased risk of 
thrombotic events in comparison to adults without ITP, as well as 
fatigue, infections, hematologic malignancies and reduced quality of 
life.5  
The diagnosis of ITP is made when all other causes of thrombocytopenia 
are ruled out.  
 
The therapy objectives are to achieve a safe number of platelets (often 
>30x109/L), to avoid life-threatening bleeding and long-term treatment, 
and to sustain a normal quality of life.1 The therapy should be tailored 
according to the clinical presentation, presence of additional bleeding 
risk factors (such as anticoagulant therapy, dialysis, surgical 
procedures), comorbidities, individual side effect tolerance, as well as 
the platelet count. Treatment should begin when the platelet count is 
<30x109/L, or when bleeding symptoms present in spite of a high 
thrombocyte count (Table 1).6-7  
 
Splenectomy is reserved for patients unresponsive to or intolerant to 
corticosteroids. By performing splenectomy, antibody-coated platelets 
are no longer removed via the spleen and spleen antiplatelet antibodies 
are no longer produced. Splenectomy should be postponed, if possible, 
for 6–12 months, considering a possible spontaneous or therapeutically 
induced remission.1,6,8-9 Good therapeutic response is achieved in 60–
80% of patients with ITP.8 Even though there is a consensus regarding 
the short-term efficacy of splenectomy, findings on its long-term 
efficacy and side-effects are controversial. Particular studies show that 
splenectomy leads to long-term remission in 60–80% of patients, while 
other studies imply that all patients with ITP relapse after a sufficiently 
long follow-up period. In most published studies, remission is achieved 
in 60% of patients, with 75% of relapses recorded in the first 4 years. 
The response was achieved in 83% of patients who needed further 
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treatment after splenectomy, which implied that splenectomy can 
convert a drug-resistant patient to a patient with a good response.10    
Currently, there are many therapeutic modalities for patients resistant 
to splenectomy. Approximately 75% of patients with refractory ITP 
eventually achieve remission, although it occurs slowly. Patients who 
do not achieve remission instead experience an extremely difficult 
disease course with significant morbidity and mortality rates. It is 
possible that newer forms of treatment, such as rituximab, 
thrombopoietic factors, and monoclonal antibodies, may alter the 
outcomes for this extremely resistant subgroup.11  
 
The aim of our study was to establish the frequency of resistance and 
relapse after splenectomy, the occurrence of bleeding, infections and 
thrombotic events, the therapeutic strategies and the drug efficacy in 
a group of patients with splenectomy-resistant ITP. 
 
Table 1. The Therapy of Immune Thrombocytopenia (ITP).6 
 
First–line 
management 
(initial treatment) 
• corticosteroids (prednisone, methylprednisolone, 
dexamethasone) 
• intravenous immunoglobulins (IVIg) 
Second-line 
management 
• splenectomy  
• azathioprine; cyclosporine A; vinca alkaloids; 
cyclophosphamide; thrombopoietin receptor agonist (TPO-
RAs); mycophenolic acid; danazol; dapsone; rituximab 
Third-line 
management 
(for refractory ITP) 
Category A: 
• thrombopoietin receptor agonists (TPO-RAs) 
Category B: 
• combination of medications from the 1st and 2nd line 
management 
 
Patients and Methods 
We retrospectively analyzed 138 adult patients with ITP who had been 
previously diagnosed and treated at the Clinic of Hematology, Clinical 
Center of Serbia, and who underwent splenectomy between 1987 and 
2018. The following laboratory tests were run for each patient: blood 
tests - erythrocyte, leukocyte and platelet (PLT) counts, hemoglobin 
value, and leukocyte formula, hemostasis tests - fibrinogen, 
prothrombin time (PT), activated partial thromboplastin time (aPTT), 
morphological and cytochemical analysis of the bone marrow, thyroid 
status, abdominal ultrasonography and platelet kinetics (in most 
patients). Splenectomy was indicated in cortico-resistant (PLT<30x109/L) 
or cortico-sensitive patients. In order to attain the recommended 
platelet count for splenectomy (PLT>50x109/L), patients were 
premedicated with corticosteroids, intravenous immunoglobulins (IVIg) 
and platelet transfusions. A “Complete response” (CR) is defined by 
the IWG as any platelet count of at least 150x109/L. “Partial response” 
(PR) is defined as any platelet count >50x109/L. Refractory ITP is defined 
as any platelet count <30x109/L. Relapse is defined as any platelet count 
<150x109/L in patients who previously achieved a CR or 50x109/L in 
patients who previously achieved a PR.2 The software used for the 
statistical analysis was “Microsoft Office Excel 2007” 
 
Results 
In this retrospective study, we analyzed 138 patients with adult ITP who 
had been previously diagnosed, treated and splenectomized at the 
Clinic of Hematology, Clinical Center of Serbia, from 1983 to 2018. From 
138 patients who were splenectomized, 28 (20.3%) were refractory to 
splenectomy. Of these, 16 (11.6%) relapsed and 12 (8.7%) had no 
response (Figure 1). The average follow-up period after splenectomy 
was 117 months (3-474). Only one patient (0.79%) was observed for 
less than a year. We observed 37.8% (n=52/138) of the patients for 
longer than 5 years, and 40% (n=55/138) for more than 10 years. 
 
Hemorrhagic syndrome developed in 22/28 (78.6%) patients. Patients 
most commonly had hematomas, petechiae, and ecchymoses (61%, 
n=17/28), epistaxes and gingival bleeding (18%, n=5/28), menorrhagias 
and metrorrhagias (18%, n=5/28). There was no reported intracranial 
hemorrhage. Incidence and localization of bleeding are shown in Figure 3. 
Non-hemorrhagic complications or other comorbidities were recorded in 8 
(28.6%) patients: Non-Hodgkin’s lymphoma (2/28, 7,1%), acute renal 
failure (1/28, 3.6%), systemic lupus erythematosus (1/28, 3,6%), 
abscesses (2/28, 7.1%) or infections (3/28, 10.7%). There were no 
reported death outcomes. 
 
Figure 1. Patient Distribution Relative to Splenectomy Response. 
 
Legend: CR = complete response. PR = partial response. 
 
The average follow-up period of the patients resistant to splenectomy 
was 147 months (23-474). Most relapses occurred in the first year after 
splenectomy (6/28, 21.4%), while in one patient (1/28, 3.6%) relapse 
occurred after 18 years (Figure 2). Laparotomy was performed in 64% 
(n=18/28) of the patients, and laparoscopy was performed in 36% 
(n=10/28) of the patients, with no significant differences in response. 
Of the patients refractory to splenectomy, 67.8% (n=19/28) showed a 
good therapeutic response: 49% (n=14/28) complete remission and 
18.8% (n=5/28) partial remission. 
 
Figure 2. Relapse Incidence after Splenectomy. 
 
 
 
Figure 3. Incidence and Localization of Bleeding. 
 
 
Out of the 28 splenectomized patients with refractory ITP, 27 patients 
underwent further treatment. Therapeutic lines and modalities are 
shown in Figure 4, and the therapeutic effect is shown in Figure 5. 
Prednisone was used in 22 patients (81.5%) and lead to a good 
therapeutic response (CR+PR) in 9 patients (40.9%). Romiplostim was 
used in 2 patients (7.4%) who achieved a good response (100%). 
Eltrombopag was used in 4 patients (14.81%), leading to a good 
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therapeutic response in 3 patients (75%). Cyclosporine was used in 3 
patients (11.1%), leading to a good therapeutic response in 2 patients 
(66.7%). Mycophenolic acid was used in 5 patients (18.5%), leading to 
a good therapeutic response in 3 patients (60%). Danazol was used in 
6 patients (22.2%), leading to a good therapeutic response in 3 patients 
(50%). Azathioprine was used in 11 patients (40.7%), leading to a good 
therapeutic response in 4 patients (36.4%). Cyclophosphamide was 
used in 4 patients (14.8%) with only one patient (25%) achieving a good 
therapeutic response. Dapsone was used in one patient (3.7%) without 
response. Excision of an accessory spleen was performed in one patient 
(3.7%) without effect. Vinca alkaloids were prescribed in 5 patients 
(18.5%), with only one patient (20%) achieving a good therapeutic 
response. 
 
Figure 4. Distribution of Patients based on the Employed Therapeutic 
Modalities after Splenectomy. 
 
 
Legend: TPO-RAs = Thrombopoietin Receptor Agonists. 
 
Figure 5. The Effect of Therapy. 
 
 
Legend: CR = complete response. PR = partial response. NR = no response. 
 
Discussion 
Our study included 138 adult patients with ITP, out of whom 20.3% 
(n=28/138) were refractory to splenectomy. Relapse occurred in 11.6% 
(n=16/138) of patients, whilst 8.7% (n=12/138) of patients had no 
response to splenectomy. The average follow-up period of patients 
resistant to splenectomy was 147 months (23-474). Most relapses 
occurred in the first year after splenectomy (n=6/28, 21.4%), while in 
one patient (3.6%) relapse occurred after 18 years. The study of 
Mcmillan et al., which involved 105 ITP patients refractory to 
splenectomy, reports a frequent occurrence of relapse (66%), most 
often in the first 3 months after splenectomy (45% of patients), and no 
response in 22% of cases after splenectomy was performed.11 Vianelli 
et al., who studied 233 splenectomized patients, reports a relapse rate 
of 75% (after 48 months) and no response in 40% of cases.12 In the 
retrospective study of Ahmed et al., involving 167 patients, relapse 
occurred in 30% of the cases (after 54 months) and 14% of the patients 
experienced no response.13  
 
After splenectomy, our study reported a good therapeutic response 
with different therapeutic modalities in 67.8% of the patients: CR 49% 
and PR 18.8%, similarly to Mcmillan’s study (71.4%).11 A stable 
therapeutic response was achieved with the following medications: 
romiplostim (2/2, 100%), eltrombopag (3/4, 75%), cyclosporine (2/3, 
66.67%), mycophenolic acid (3/6, 50%), danazol (3/6, 50%), prednisone 
(9/22, 40.9%). Also, 29.6% (8/27) of the patients had no response to 
therapy. Mcmillan et al. showed that a stable therapeutic response was 
achieved with following medications: danazol (33.9%), 
cyclophosphamide (25.7%), prednisone (19%), and azathioprine 
(15.8%); 28% of the patients did not respond to therapy. The percentage 
of patients resistant to all therapeutic modalities is similar in both 
studies.11 However, Mcmillan’s study does not take TPO-RAs into 
consideration, which may be the reason for the discrepancy between 
our studies. In the study of Saleh et al., 299 patients (115 
splenectomized) were treated for 3 years with eltrombopag. Good 
therapeutic effect was noted in 80% (92/115) of the splenectomized 
patients, as well as in 50% of the multi-resistant patients (treated with 
more than 4 therapeutic lines). The effect was maintained for 2 years.14 
In the research of Kuter et al., 292 ITP patients (95 splenectomized) 
were treated with romiplostim for 5 years with a good therapeutic effect 
in 67% (64/95) of the splenectomized patients. The effect was 
maintained for 2 years also.15 Consequently, the results of our study 
coincide with results of Saleh et al., as well as with the results of Kuter 
et al. Our study reported hemorrhagic syndromes in 22/28 (78.6%) of 
the patients: hematomas, petechiae, ecchymoses (61%), epistaxes and 
gingival bleedings (18%), menorrhagias and metrorrhagias (18%), with 
no intracranial hemorrhage reported. Non-hemorrhagic complications 
or comorbidities were seen in 8 (28.6%) of the patients: Non-Hodgkin’s 
lymphoma 2/28 (7.1%), acute renal failure 1/28 (3.6%), systemic lupus 
erythematosus 1/28 (3.6%), abscesses 2/28 (7.1%) and infections 3/28 
(10.7%). There were no reported death outcomes. Mcmillan et al. did 
not describe morbidity, but only a mortality regarding hemorrhagic 
events of 10% (intracranial hemorrhage 90%), malignancy and 
cardiovascular disease 13.9%. Other noted complications/comorbidities 
in Mcmillan’s study were deep venous thrombosis (12.4%), systemic 
lupus erythematosus (2.9%), Non-Hodgkin’s lymphoma (1.9%) and 
Hodgkin’s lymphoma (2.9%).11 The study of Saleh et al reported a lower 
incidence of hemorrhagic complications after the use of eltrombopag 
(from 56% to 11% during the next 3 years), thromboembolic events 
(4%) and elevation of liver enzymes (2%).14 The study of Kuter et al, 
reported hemorrhagic complications in 57% of the patients: hematomas 
and petechiae (32%), epistaxes and gingival bleeding (41%).15 In 
comparison, our study had a higher incidence of complications, but 
without death outcomes. 
 
Conclusion 
Splenectomy represents a very efficient therapeutic modality for 
patients with ITP. Patients who remained resistant after splenectomy 
had a higher rate of CR. In our study, 20.3% of the patients were 
refractory to splenectomy, out of whom 11.6% relapsed (with the 
highest incidence in the first year after splenectomy, 21.4%), and 8.7% 
were resistant to splenectomy. Our research showed that 67.8% of the 
patients refractory to splenectomy achieved a good therapeutic 
response (49% CR and 18.8% PR). A stable therapeutic response was 
achieved with the following medications: romiplostim (100%), 
eltrombopag (75%), cyclosporine (66.67%), mycophenolic acid (50%), 
danazol (50%), prednisone (40.9%). Thus, thrombopoietin receptor 
agonists exhibited the greatest success so far in treating patients with 
refractory ITP. The limitations of our study were a small sample of 
patients with a resistant form of ITP treated with thrombopoietin 
receptor agonists, as well as a heterogeneous follow-up period after 
splenectomy. 
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